SCHEMBL3330293

SCHEMBL3330293

CCSCCOC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1c1ccc(C(=O)OC)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.63
ALDH1A1 P00352 11/20 0.63
CASP1 P29466 5/20 0.63
CASP7 P55210 4/20 0.63
MAPK1 P28482 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TDP1 Q9NUW8 1/20 0.61
HSD17B10 Q99714 7/20 0.58
HPGD P15428 4/20 0.58
GAA P10253 3/20 0.54
HTT P42858 1/20 0.54
ALOX15 P16050 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
BAP1 Q92560 1/20 0.52
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23009264 0.89 ALDH1A1 (0.64) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3323056 0.89 KDM4E (0.74) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3325232 0.82 KDM4E (0.59) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3327812 0.80 MAPK1 (0.70) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3325228 0.80 ALDH1A1 (0.81) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3329187 0.79 KDM4E (0.80) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3323236 0.79 ALDH1A1 (0.80) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3324841 0.78 ALDH1A1 (0.79) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3326647 0.78 ALDH1A1 (0.75) KDM4EALDH1A1CASP1CASP7MAPK1
SCHEMBL3329777 0.78 ALDH1A1 (0.78) KDM4EALDH1A1CASP1CASP7MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885ALDH1A1 2615/4885CASP1 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.